Aflibercept for diabetic macular edema

References

• Centers for disease Control and Prevention blindness caused by diabetes-Massachusetts, 1987-1994. JAMA 1996;276:1865-6
   Web of Science ®Google Scholar
• Kempen JH, O´Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122:552-63
   PubMed Web of Science ®Google Scholar
• Patz A, Schatz H, Berkow JW, et al. Macular edema- an overlooked complication of diabetic retinopathy. Trans AM Acd Ophthalmol Otolaryngol 1973;77:34-42
   Google Scholar
• King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31
   PubMed Web of Science ®Google Scholar
• Murata T, Ishibashi T, Khalil A, et al. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res 1995;27:48-52
   PubMed Web of Science ®Google Scholar
• Khurana RN, Do DV, Nguyen QD. Anti-VEGF therapeutic approaches for diabetic macular edema. Int Ophthalmol Clin 2009;49:109-19
   PubMedGoogle Scholar
• Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29:10-14
   PubMed Web of Science ®Google Scholar
• Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol 2006;142:660-8
   PubMed Web of Science ®Google Scholar
• Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat endothelial growth factor gene by hypoxia. J Biol Chem 1995;270:13333-40
   PubMed Web of Science ®Google Scholar
• Liu Y, Cox SR, Morita T, Kourenbamnas S. Hypoxia regulates vascular endotelial growth factor gene expression in endotelial cells. Identification of a 5´ enhacer. Circ Res 1995;77:638-43
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611
   PubMed Web of Science ®Google Scholar
• Ford JA, Elders A, Shyangdan D, et al. The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review. BMJ 2012;345:e5182
   PubMed Web of Science ®Google Scholar
• Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema. Ophthalmology 2004;111:218-25
   PubMed Web of Science ®Google Scholar
• Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128:289-96
   PubMed Web of Science ®Google Scholar
• Vinores SA. Anti-VEGF therapy for ocular vascular diseases. In: Maragoudakis ME, Papadimitriou E, editors.Angiogenesis: basic science and clinical applications.Transworld Reserch Network;Kerala, India:2007. Chapter 28 p. 467-82
   Google Scholar
• Huang H, Shen J, Vinores SA. Blockage of VEGFR1 and 2 supresses pathological angiogenesis and vascular leakage in the eye. PLoS One 2011;6:e21411
   Web of Science ®Google Scholar
• Noma H, Funatsu H, Mimura T, et al. Soluble vascular endotelial growth factor receptor-2 and inflammatory factors in macular edema with branch retinal vein occlusion. Am J Ophthalmol 2011;152:669-77
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularization: 2 years findings of the IVAN randomized controlled trial. Lancet 2013;382:1258-67
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2012;119:1388-98
   PubMed Web of Science ®Google Scholar
• Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL Noninferiority Randomized Trial. Ophthalmology 2013;120:2300-9
   PubMed Web of Science ®Google Scholar
• Krebs I, Schmetterer L, Boltz A, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 2013;97:3266-71
   Web of Science ®Google Scholar
• Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: re-port 3. Arch Ophthalmol 2012;130:972-9
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-8
   PubMed Web of Science ®Google Scholar
• Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 2003;9:47-52
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-48
   PubMed Web of Science ®Google Scholar
• Korobelnik JF, Holz FG, Roider J, et al. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results from phase 3 GALILEO study. Ophthalmology 2014;121:202-8
   PubMed Web of Science ®Google Scholar
• Heier JS, Clarck WL, Boyer DS, et al. Intravitreal Aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 2014. [Epub ahead of print]
   Google Scholar
• Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:1522-
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Browning DJ, et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology 2009;116:2141-8
   PubMed Web of Science ®Google Scholar
• Do DV, Nguyen QD, Shah SM, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br J Ophthalmol 2009;93:144-9
   PubMed Web of Science ®Google Scholar
• Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 2011;118:1819-26
   PubMed Web of Science ®Google Scholar
• Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012;119:1658-65
   PubMed Web of Science ®Google Scholar
• Massin P, Bandello F, Garwec JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study). Diabetes Care 2010;33:2399-405
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Kaiser P, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninty-six-week results of the VIEW studies. Ophthalmology 2014;121:193-201
   PubMed Web of Science ®Google Scholar